Retatrutide is still in clinical development. Its safety profile is drawn from trials of a few hundred to a few thousand participants and is not fully established. This page is educational context, not a substitute for the monitoring that happens inside those trials.
Overview
The most common retatrutide side effects reported in trials are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which were dose-related and mostly mild to moderate in the phase 2 obesity trial (Jastreboff et al., NEJM 2023, n=338). The signal specific to retatrutide's triple-agonist design is an increase in heart rate, which peaked around 24 weeks of treatment before declining. Long-term risks are still being characterized — which is exactly what an unapproved drug means in practice.
Gastrointestinal effects
Like semaglutide and tirzepatide, retatrutide slows gastric emptying and suppresses appetite, and the gut is where that shows up first:
- In the phase 2 obesity trial, GI events were the most frequent adverse events, tracked with dose, and were mostly mild to moderate; trials mitigate them by starting low and escalating slowly (NEJM 2023).
- In the phase 2 type 2 diabetes trial (n=281), 35% of retatrutide-treated participants reported mild-to-moderate GI events — nausea, diarrhea, vomiting, constipation (Rosenstock et al., The Lancet 2023).
- In the phase 3 diabetes trial, GI events were again the most frequent, generally mild to moderate, subsided over time, and led 2–5% of retatrutide participants to discontinue (The Lancet 2026).
The heart-rate signal
Retatrutide's distinguishing pharmacology — glucagon-receptor agonism — is also its distinguishing safety question. In the phase 2 obesity trial, heart rate increased on treatment, peaked at 24 weeks, and declined thereafter (NEJM 2023). GLP-1 drugs raise heart rate modestly on their own; the glucagon arm can add to that, so cardiovascular monitoring is built into the trial protocols. The clinical significance of a transient heart-rate rise is precisely the kind of question the dedicated cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes, NCT06383390) exists to answer.
What the trials did not see
Some reassuring negatives from the published trials, with the caveat that they involve limited numbers and durations:
- No severe hypoglycemia and no deaths were reported in the phase 2 diabetes trial, despite glucagon's glucose-raising activity (The Lancet 2023).
- The phase 3 diabetes trial likewise reported no severe hypoglycemia (The Lancet 2026).
Absence of a signal in a 281- or 537-person trial is not proof of absence in a population of millions — that distinction is why regulators require large outcome programs before approval.
What is still unknown
The honest summary is that retatrutide's risk profile is incompletely defined. Open questions include long-term cardiovascular outcomes, kidney outcomes, effects in populations excluded from trials, rare adverse events that only surface at scale, and everything the incretin class is monitored for on approved labels (pancreatitis, gallbladder disease, thyroid C-cell findings in rodents). For context on how the class is assessed long-term, see are GLP-1 peptides safe long term.
The gray-market problem
Because retatrutide is approved nowhere, there is no pharmaceutical-grade product outside its trials — yet vials labeled "retatrutide" are widely sold. That stacks a second risk layer on top of the drug's own unknowns:
- Identity, dose accuracy, purity, and sterility are unverified by any regulator.
- The FDA has warned about unapproved GLP-1 class drugs sold for weight loss outside the legitimate supply chain (FDA).
- Self-directed use means no heart-rate or metabolic monitoring — the safeguards that made the trial safety data interpretable in the first place.